Margin Pressures And Partnership Wins Will Shape Next-Year Performance Outlook

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 Aug 24

Updated

11 Dec 25

Views

130

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-17.3%

7D

-5.7%

Loading

1Y

-17.3%

7D

-5.7%

You can edit this narrative until Dec 12 4:10 PM. Then, changes will post as Updates.

Author's Valuation

US$206.1915.7% undervalued

AnalystConsensusTarget Fair Value

Shared on 11 Dec 25

ICLR: Bookings Momentum Will Offset 2026 Margin And Pricing Headwinds

Analysts have modestly trimmed their blended price target on ICON, reflecting a slightly lower valuation multiple as they balance ongoing concerns about 2026 margin and pricing headwinds, highlighted in recent target cuts such as TD Cowen's move to $172 from $183 and Leerink's to $220 from $235, against still-supportive views on bookings momentum and long term growth prospects. Analyst Commentary Bullish Takeaways Bullish analysts highlight that updated models following Q3 results support modest upside to fair value, even after factoring in near term margin noise.

Shared on 27 Nov 25

Fair value Decreased 1.00%

ICLR: Bookings Momentum And Leadership Transition Will Drive Renewed Confidence In 2025

ICON’s analyst price target was revised modestly downward from $208.27 to $206.19, as analysts cited ongoing concerns about margin pressure and potential headwinds for 2026. These concerns were partially tempered by encouraging booking trends and updated financial models following recent quarterly results.

Shared on 08 Nov 25

Fair value Decreased 0.32%

ICLR: Operational Resilience And Leadership Transition Will Support Momentum Next Year

The analyst price target for ICON has edged lower by approximately $0.67 to $208.27, as analysts cite ongoing concerns about margin pressure and a slightly more cautious revenue growth outlook. Analyst Commentary Analyst sentiment on ICON remains divided, with both encouraging signals and pressing concerns for investors to consider.

Shared on 24 Oct 25

Fair value Decreased 3.12%

The analyst fair value estimate for ICON has been revised downward by approximately $7 to $208.93. Analysts cite ongoing concerns about margin pressure and future revenue growth challenges.

Shared on 13 Sep 25

Fair value Decreased 2.15%

ICON’s consensus price target has been revised down from $220.40 to $215.67 as analysts express caution over persistent revenue and booking growth risks, customer cancellations, and macro uncertainty, which offset recent partnership gains and stable sector demand. Analyst Commentary Bearish analysts highlighted persistent revenue and EBITDA growth risks in 2026 tied to lower-than-normal book-to-bills (BtBs) and customer cancellations, with consensus estimates seen as too optimistic.

Shared on 07 May 25

Fair value Increased 3.45%

Shared on 30 Apr 25

Fair value Increased 1.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 1.82%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 10%

AnalystConsensusTarget has decreased revenue growth from 4.2% to 3.7%.

Shared on 09 Apr 25

Fair value Increased 35%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 28%

Shared on 26 Mar 25

Fair value Decreased 1.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 40%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 0.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$206.19

15.7% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

3.15%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.94%

Calculation

US$910.73m

Earnings '28

x

18.71x

PE Ratio '28

=

US$17.04b

Market Cap '28

US$17.04b

Market Cap '28

/

64.55m

No. shares '28

=

US$263.94

Share Price '28

US$263.94 Share Price '28

Discounted to 2025 @ 8.89% p.a.

=

US$204.42

Fair Value '25